This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claims 1-70 (canceled).

Claim 71 (currently amended): A method for treating or inhibiting atherosclerosis in a mammal by decreasing the formation or growth of atherosclerotic lesions comprising:

providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin and between E-selectin and a ligand of E-selectin; and

administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and synthetic analogs or mimetics of PSGL-1, said agent being effective to inhibit the interaction between P-selectin and a ligand of P-selectin and between E-selectin and a ligand of E-selectin.

Claim 72 (previously presented): The method of claim 71 wherein said P-selectin is on a cell.

Claim 73 (previously presented): The method of claim 72 wherein said cell is an endothelial cell.

Claims 74-76 (canceled).

Claim 77 (previously presented): The method of claim 71 wherein said PSGL-1 is on a cell, selected from the group consisting of monocytes, neutrophils, eosinophils, CD+4 T cells, CD+8 T cells, and natural killer cells.

Claim 78 (previously presented): The method of claim 71 wherein the PSGL-1 is on a leukocyte.

Claim 79 (previously presented): The method of claim 78 wherein said leukocyte is a neutrophil.

Claim 80 (previously presented): The method of claim 78 where said leukocyte is a monocyte.

Claim 81 (previously presented): The method of claim 71 wherein said P-selectin can bind to said PSGL-1 in the absence of said agent.

Claim 82 (canceled).

Claim 83 (previously presented): The method of claim 71 wherein said agent is administered in sequential exposures over a period of hours, days, weeks, months or years.

Claim 84 (previously presented): The method of claim 71 wherein said agent is administered repeatedly, or by a controlled release delivery system.

Claim 85 (previously presented): The method of claim 71 wherein said agent is administered in combination with other therapeutic agents.

Claim 86 (previously presented): The method of claim 72 wherein said cell is a platelet.

Claim 87 (previously presented): The method of claim 71 wherein said mammal is human.

Claim 88 (previously presented): The method of claim 71 wherein said agent is administered in a dose of from about 0.01 mg/kg to about 200mg/kg of body weight.

Claim 89 (previously presented): The method of claim 71 wherein said agent is administered at a dose of about 100 mg/kg of body weight.

Claim 90 (currently amended): A method for treating or inhibiting atherosclerosis in a mammal by decreasing the formation or growth of atherosclerotic lesions comprising:

providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin; and

administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and synthetic analogs or mimetics of PSGL-1, said agent being effective to inhibit the interaction between P-selectin and a ligand of P-selectin.

Claim 91 (currently amended): A method for decreasing the formation or growth of atherosclerotic lesions in a mammal comprising:

providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin; and

administering an effective amount of said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and synthetic analogs or mimetics of PSGL-1, wherein said agent is administered prior to, or in conjunction with, a vessel-corrective technique.

Claim 92 (previously presented): The method of claim 91, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

Claim 93 (previously presented): The method of claim 91, wherein said agent is administered in sequential exposures over a period of hours, days, weeks, months or years.

Claim 94 (previously presented): The method of claim 91, wherein said agent is administered in combination with other therapeutic agents.

Claim 95 (currently amended): A method for treating restenosis in a mammal to which a vessel-corrective technique is administered comprising:

performing a vessel-corrective technique selected form the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery on a mammal; and

administering to said mammal, after said vessel-corrective technique, an effective amount of an agent selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and synthetic analogs or mimetics of PSGL-1, such that the restenosis occurring after said vessel-corrective technique is thereby treated.